Non-small cell lung cancer MRD:minimal residual disease
Conditions
Interventions
None listed
Sponsors
Yasuhiro Tsutani
Guardant Health Inc.
Eligibility
Inclusion criteria
Inclusion criteria: Patients who have undergone radical resection for NSCLC (including those who have undergone neoadjuvant chemotherapy) and whose pathological stage is found to be II or III. Patients whose pathological stage is II or III and who are being followed up at our department as outpatients within the past 2 years since surgery. Or patients who have undergone local therapy (surgery, radiation therapy, radiochemotherapy, ablation, etc.) with curative intent for oligorecurrence (two or fewer recurrent lesions) within the past 2 years.
Exclusion criteria
Exclusion criteria: Patients diagnosed with large cell neuroendocrine carcinoma (LCNEC). Patients receiving adjuvant osimertinib therapy (patients receiving single-agent immune checkpoint inhibitors can be enrolled).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To examine the minimal residual disease (MRD) detection rate, using the Guardant Reveal Assay, in NSCLC patients who receive curative-intent local treatments. | — |
Secondary
| Measure | Time frame |
|---|---|
| To examine duration between molecular recurrence, detected by the Guardant Reveal Assay, and clinical recurrence, detected by radiological examination(s) including CT scan, PET-CT, or brain MRI scan, in NSCLC patients who receive curative-intent local treatments. To examine correlation between MRD detection, using the Guardant Reveal Assay, and other potential prognostic biomarkers including tumor size, lymph node status, histological grade, and vascular invasion for patients who receive surgical resection. | — |
Contacts
Public ContactOhara Shuta
Kindai University Faculty of Medicine
Outcome results
None listed